SRDX

SurModics Inc

SRDX, USA

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

https://www.surmodics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SRDX
stock
SRDX

Groupe la Francaise Sells 33,700 Shares of Surmodics, Inc. $SRDX Defense World

Read more →
SRDX
stock
SRDX

Why analysts upgrade SRDX stock - July 2025 Highlights & Free Reliable Trade Execution Plans moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

HOLD

Target Price:

$43

Analyst Picks

Strong Buy

0

Buy

0

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

5.51

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-4.78 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.13 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

3.06 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.53

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 62.12% of the total shares of SurModics Inc

1.

BlackRock Inc

(8.0243%)

since

2025/06/30

2.

AllianceBernstein L.P.

(5.9483%)

since

2025/06/30

3.

Vanguard Group Inc

(5.6666%)

since

2025/06/30

4.

Soleus Capital Management, L.P.

(5.5188%)

since

2025/06/30

5.

Morgan Stanley - Brokerage Accounts

(4.5868%)

since

2025/06/30

6.

Readystate Asset Management LP

(3.0328%)

since

2025/06/30

7.

UBS Group AG

(2.9566%)

since

2025/06/30

8.

Gabelli Funds LLC

(2.9014%)

since

2025/06/30

9.

Hudson Bay Capital Management LP

(2.7977%)

since

2025/06/30

10.

Qube Research & Technologies

(2.7556%)

since

2025/06/30

11.

Dimensional Fund Advisors, Inc.

(2.4775%)

since

2025/06/30

12.

Geode Capital Management, LLC

(2.3517%)

since

2025/06/30

13.

State Street Corp

(2.2443%)

since

2025/06/30

14.

Balyasny Asset Management LLC

(1.9002%)

since

2025/06/30

15.

ODDO BHF Asset Management SAS

(1.8751%)

since

2025/06/30

16.

HSBC Holdings PLC

(1.866%)

since

2025/06/30

17.

Goldman Sachs Group Inc

(1.6076%)

since

2025/06/30

18.

Gabelli Securities Inc

(1.4239%)

since

2025/06/30

19.

Cnh Partners, LLC

(1.0923%)

since

2025/06/30

20.

Millennium Management LLC

(1.0884%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.